Study on predicting the efficacy of neoadjuvant therapy for ovarian cancer using OCS score based on exosome technology

Prediction of the efficacy of neoadjuvant therapy for high-grade serous ovarian cancer using OCS score based on exosome technology: a prospective multicenter study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091668

Enrollment

Unknown

Registered

2024-11-01

Start date

2024-11-01

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Case series:None

Eligibility

Sex/Gender

Female

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Women over 18 years old 2.Pathological diagnosis of stage III-IV high-grade serous ovarian cancer 3.ECOG = 4 4.Expected survival period exceeding 6 months 5.PDS is not feasible or rejected, receive neoadjuvant chemotherapy to achieve optimal tumor reductioneffect 6.Sign informed consent form

Exclusion criteria

Exclusion criteria: 1.History of cancer in the past 5 years 2.Previously received treatment for ovarian cancer 3.Gestation 4.Previous bilateral oophorectomy

Design outcomes

Primary

Measure	Time frame
R0/R1 resection;	—

Secondary

Measure	Time frame
Imaging CR/PR;Chemotherapy response score;platinum free treatment interval (PFI);PFS;OS;	—

Countries

China

Contacts

Public ContactRuixia Guo

Zhengzhou University First Affiliated Hospital

grxcdxzzu@163.com+86 135 2556 9376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026